Duration of Use Among New Users of Hydrochlorothiazide (HCTZ), Angiotensin-Converting Enzyme Inhibitors (ACEIs), and Angiotensin II Receptor Blockers (ARBs)

Project Title Duration of Use Among New Users of Hydrochlorothiazide (HCTZ), Angiotensin-Converting Enzyme Inhibitors (ACEIs), and Angiotensin II Receptor Blockers (ARBs)
Date Posted
Friday, April 19, 2019
Project ID
cder_mpl1p_wp023
Status
Complete
Deliverables
Description

This report contains estimates of hydrochlorothiazide (HCTZ), angiotensin-converting enzyme inhibitor (ACEI), and angiotensin II receptor blocker (ARB) utilization in the Sentinel Distributed Database (SDD). Data from January 1, 2000 to June 30, 2018 from 17 Data Partners contributing to the SDD were included in this report. This request was distributed to Data Partners on August 20, 2018.

Medical Product
angiotensin II receptor blocker (ARB)
angiotensin-converting enzyme (ACE) inhibitor
hydrochlorothiazide (HCTZ)
Population / Cohort
All individuals
Time Period
January 1, 2000 - June 30, 2018
Assessment Type
Exploratory Analyses
Study Type
Modular Program
Data Sources
Sentinel Distributed Database (SDD)
FDA Center
CDER